Delton Family Distinguished Professor in Organic Chemistry, and Joshua Munger, professor in the Department of Biochemistry and Biophysics and an expert in cancer cell metabolismare exploring ways to refine potential drugs that could inhibit this process and improve outcomes for patients

Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)

Presented for research literature review only Iqbal J et al
Because they are game birds, we are not permitted to band bobwhite
Longitudinal analyses from the Phase 2 and Phase 3 trials show that the incidence of new-onset nausea and vomiting peaked during the first 4-8 weeks of treatment and then declined substantially during the maintenance phase